BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pozzilli P, Carotenuto P, Delltala G. Lymphocytic traffic and homing into target tissue and the generation of endocrine autoimmunity. Clin Endocrinol 1994;41:545-54. [DOI: 10.1111/j.1365-2265.1994.tb01816.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Bossowski A, Stasiak-Barmuta A, Czarnocka B, Urban M, Dadan J. Application of mouse monoclonal antibodies for identification of antigen regions of human thyroid peroxidase in adolescents with Graves' disease and non-toxic multinodular goiter by flow cytometry. Autoimmunity 2005;38:605-11. [PMID: 16390813 DOI: 10.1080/08916930500315084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
2 Itoh M, Uchimura K, Makino M, Kobayashi T, Hayashi R, Nagata M, Kakizawa H, Fujiwara K, Nagasaka A. Production of IL-10 and IL-12 in CD40 and interleukin 4-activated mononuclear cells from patients with Graves' disease. Cytokine 2000;12:688-93. [PMID: 10843746 DOI: 10.1006/cyto.1999.0659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
3 Papaccio G, Latronico MV, Pisanti FA, Federlin K, Linn T. Adhesion Molecules and Microvascular Changes in the Nonobese Diabetic (NOD) Mouse Pancreas. An NO-Inhibitor ( L -Name) is Unable to Block Adhesion Inflammation-Induced Activation. Autoimmunity 2009;27:65-77. [DOI: 10.3109/08916939809008037] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
4 Yamamoto K, Itoh M, Okamura T, Kimura M, Yokoyama A, Yoshino Y, Makino M, Hayakawa N, Suzuki A. Relative Levels of the Inflammatory Cytokine TNFα and the Soluble CD40 Ligand Profile in Serum Correlate with the Thyrotoxic Activity of Graves' Disease. Thyroid 2012;22:516-21. [DOI: 10.1089/thy.2011.0222] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
5 Qi Y, Li X, Zhang Q, Huang F, Lin D, Zhou Y, Hong J, Cui B, Wang W, Ning G, Wang S. Increased chemokine (C-C motif) ligand 21 expression and its correlation with osteopontin in Graves' disease. Endocrine 2015;50:123-9. [PMID: 25771884 DOI: 10.1007/s12020-015-0552-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Diserio GP, Nowotny E. Experimental Autoimmune Prostatitis: In Vivo Induction of the Autoimmune Response to Lymphocytic Soluble Factors. Alterations at the Endocrine Metabolism Level. American Journal of Reproductive Immunology 1998;39:226-34. [DOI: 10.1111/j.1600-0897.1998.tb00358.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
7 Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P. Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. European Journal of Pharmacology 1998;357:221-5. [DOI: 10.1016/s0014-2999(98)00574-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
8 Itoh M, Uchimura K, Hayakawa N, Makino M, Hayashi R, Nagata M, Kakizawa H, Nagasaka A, Sakamoto H, Kuzuya H. Surface expression and release of soluble forms of CD8 and CD23 in CD40- and IL-4-activated mononuclear cells from patients with Graves' disease (GD). Clin Exp Immunol 1998;113:309-14. [PMID: 9717983 DOI: 10.1046/j.1365-2249.1998.00658.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
9 Resetkova E, Nishikawa M, Mukuta T, Arreaza G, Fornasier VL, Volpé R. Homing of 51 Cr-Labeled Human Peripheral Lymphocytes to Graves' Thyroid Tissue Xenografted into SCID Mice. Thyroid 1995;5:293-8. [DOI: 10.1089/thy.1995.5.293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
10 Sonnet E, Massart C, Gibassier J, Allannic H, Maugendre D. Longitudinal study of soluble intercellular adhesion molecule-1 (ICAM-1) in sera of patients with Graves' disease. J Endocrinol Invest. 1999;22:430-435. [PMID: 10435852 DOI: 10.1007/BF03343586] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Bossowski A, Stasiak-Barmuta A, Urban M. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease. Horm Res 2005;64:189-97. [PMID: 16220002 DOI: 10.1159/000088875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
12 Arao T, Morimoto I, Kakinuma A, Ishida O, Zeki K, Tanaka Y, Ishikawa N, Ito K, Ito K, Eto S. Thyrocyte proliferation by cellular adhesion to infiltrating lymphocytes through the intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 pathway in Graves' disease. J Clin Endocrinol Metab 2000;85:382-9. [PMID: 10634414 DOI: 10.1210/jcem.85.1.6320] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Peng Y, Qi Y, Huang F, Chen X, Zhou Y, Ye L, Wang W, Ning G, Wang S. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave's disease. Oncotarget 2016;7:78680-7. [PMID: 27637079 DOI: 10.18632/oncotarget.12019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Faull RJ. Adhesion molecules in health and disease. Australian and New Zealand Journal of Medicine 1995;25:720-30. [DOI: 10.1111/j.1445-5994.1995.tb02861.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
15 Uchimura K, Itoh M, Yamamoto K, Imamura S, Makino M, Kato T, Fujiwara K, Sawai Y. The effects of CD40- and interleukin (IL-4)-activated CD23+ cells on the production of IL-10 by mononuclear cells in Graves' disease: the role of CD8+ cells. Clin Exp Immunol 2002;128:308-12. [PMID: 11985521 DOI: 10.1046/j.1365-2249.2002.01818.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
16 Itoh M, Uchimura K, Yamamoto K, Makino M, Imamura S, Kobayashi T, Fujiwara K, Kato T, Hayakawa N, Sawai Y, Nagasaka A, Iwase K, Nomura T, Hagino Y. Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' patients. Cytokine 2002;19:107-14. [PMID: 12242076 DOI: 10.1006/cyto.2002.1055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Qi Y, Li X, Ma X, Xu L, Zhang X, Jiang X, Hong J, Cui B, Ning G, Wang S. The role of osteopontin in the induction of the CD40 ligand in Graves' disease. Clin Endocrinol (Oxf) 2014;80:128-34. [PMID: 23617736 DOI: 10.1111/cen.12229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]